Lexotan (Bromazepam)

Bromazepam binds to the benzodiazepine site on the GABA‑A receptor complex, enhancing the natural inhibitory action of GABA. This increased chloride ion flow reduces neuronal firing, producing a calming effect that alleviates anxiety and promotes sleep.

The appropriate dose of Lexotan is determined individually by a qualified prescriber based on the patient’s condition, age, response to therapy, and any concurrent medications. Dosage adjustments are made according to clinical judgment.

Safety data for bromazepam during pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Lexotan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lexotan (bromazepam) is similar in effect to other benzodiazepines such as diazepam, but it is generally considered to have a moderate duration of action and a potency that may allow lower dosing. Choice among agents depends on factors like onset speed, half‑life, patient tolerance and specific clinical needs.

Lexotan tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Lexotan is supplied as oral tablets. The tablet should be swallowed whole with a glass of water, preferably with or without food as directed by the prescriber. Do not crush, chew, or split the tablet unless specifically instructed.

Serious risks include respiratory depression, especially when combined with other central nervous system depressants, severe allergic reactions such as anaphylaxis, and the potential for dependence or withdrawal seizures if the medication is stopped abruptly after prolonged use.

Lexotan should be avoided in individuals with known hypersensitivity to bromazepam or other benzodiazepines, patients with severe acute narrow‑angle glaucoma, and those with significant respiratory insufficiency. Caution is also advised for patients with a history of substance misuse or severe hepatic impairment.